Share on LinkedInShare on LinkedIn

ARTICLE · 07 JUNE 2016

Court Decides That ANDA Approved Before Patent Issued Cannot Infringe 35 U.S.C. § 271(e)(2)(A)

BakerHostetler
BakerHostetler
Contributor
BakerHostetler

BakerHostetler

Recognized as an innovator and one of the top firms for client service, BakerHostetler helps...

View firm profile
Explore more from BakerHostetler

Although the Hatch-Waxman Act was passed by Congress decades ago, it still produces new questions.

United StatesIntellectual Property

Although the Hatch-Waxman Act was passed by Congress decades ago, it still produces new questions. Despite vigorous argument by the patent owner, a district court dismissed a count alleging that the ANDA-filer infringed under 35 U.S.C. § 271(e)(2)(A), leaving in place the unchallenged count for infringement under § 271(a). Ferring B.V. v. Actavis, Inc., Civil Action No. 15-4222 (D.N.J. May 26, 2016).

The FDA approved Ferring's NDA for tranexamic acid formulations on November 13, 2009. Defendant Watson Laboratories filed its Abbreviated New Drug Application (ANDA) on July 23, 2010, seeking FDA approval to market generic tranexamic acid. The United States Patent and Trademark Office published Ferring's patent application on May 7, 2012, but it did not issue the patent until June 23, 2015, three and a half years after the FDA approved Watson's ANDA and Watson began marketing its generic product on January 3, 2013. After Ferring filed its complaint alleging infringement

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from